{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019156", "CSN": null, "TRF": "ORD_1308441_01", "MRN": "45579666", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1050700", "clinicalId": "1052071", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1308441_01", "SampleName": "US1257626.01", "Version": "0", "Sample": {"FM_Id": "ORD_1308441_01", "SampleId": "US1257626.01", "BlockId": "S110-77326B", "TRFNumber": "ORD_1308441_01", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2022_02_23", "processSites": {"processSite": [{"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98653", "MRN": "45579666", "FullName": "\u674e\u654f\u73b2", "FirstName": "45579666", "LastName": "45579666", "SubmittedDiagnosis": "Metastatic sarcoma, Lung", "Gender": "Female", "DOB": "1967_04_28", "OrderingMD": "\u9673\u4e09\u5947", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2021_09_08", "ReceivedDate": "2022-03-11 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "17", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "BRCA2", "isVUS": "true", "variantName": "D293E"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "T532M"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "E457del"}, {"geneName": "FANCA", "isVUS": "true", "variantName": "K1297N"}, {"geneName": "FBXO11", "isVUS": "true", "variantName": "Q29_P32del"}, {"geneName": "GPR124", "isVUS": "true", "variantName": "K1288del"}, {"geneName": "JAK3", "isVUS": "true", "variantName": "R222H"}, {"geneName": "P2RY8", "isVUS": "true", "variantName": "M16K"}, {"geneName": "PCLO", "isVUS": "true", "variantName": "V71A"}, {"geneName": "SETBP1", "isVUS": "true", "variantName": "Y994*"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "TSC2", "Include": "true", "Alterations": {"Alteration": {"Name": "deletion exons 4_7", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "deletion exons 4_7"}}, "Interpretation": "The tumor suppressor protein Tuberin (TSC2) binds with Hamartin (TSC1) to inhibit mTOR signaling and cell growth (Inoki et al., 2003; 12869586, Tee et al., 2003; 12906785). Alterations such as seen here may disrupt TSC2 function or expression (Hodges et al., 2001; 11741833, Jozwiak, 2006; 16206276, Li et al., 2004; 15340059). TSC2 mutation or homozygous deletion was not observed in any of 207 sarcoma cases in one genomic study (cBio_Barretina et al., 2010; 20601955). TSC2 mutations have been described in chordomas, perivascular epithelioid cell tumors, uterine angiosarcoma, and rhabdoid tumors, among others (Lee_Jones et al., 2004; 15236319, Dickson et al., 2013; 22927055, Hayashi et al., 2012; 22748302, Lee et al., 2012; 22797305). The mTOR pathway is frequently activated in various sarcomas (Ando et al., 2013; 24216993, Zenali et al., 2009; 19429803, Zhang et al., 2013; 23714727, Brewer et al., 2012; 22821997, Patel, 2013; 23605780). Published data investigating the prognostic implications of TSC2 alterations in sarcomas are limited (PubMed, Jan 2022). Loss or inactivation of TSC2 can activate mTOR signaling (Tee et al., 2003; 12906785). MTOR inhibitors such as everolimus, temsirolimus, and sirolimus have shown activity against tumors associated with the genetic disease tuberous sclerosis complex (TSC), including subependymal giant cell astrocytomas and renal angiomyolipomas (Kwiatkowski et al., 2015; 25782670, Luo et al., 2021; 34217357, Choi et al., 2020; EAU Abstract 103, Wang et al., 2020; 31597506, Guo et al., 2021; 33575217, Espinosa et al., 2018; 29764404, Chuang et al., 2017; 28547571). Sirolimus and nab_sirolimus have shown activity for patients with TSC2_altered malignant perivascular epithelioid cell tumors (PEComas) (Wagner et al., 2010; 20048174, Dickson et al., 2013; 22927055, Wagner et al., 2021; 34637337). Nab_sirolimus has also shown limited activity for patients with TSC2_mutated sarcomas (Dickson et al., 2021; ASCO Abstract 3111). In the context of TSC2_altered malignancies unrelated to TSC, everolimus and temsirolimus activity has been limited (Adib et al., 2021; 33727259, Nassar et al., 2020; 31653662, Voss et al., 2019; 3032730) with the exception of anecdotal reports across various solid tumors, including anaplastic thyroid cancer (Wagle et al., 2014; 25295501), renal cell carcinoma (RCC) (Tannir et al., 2015; 26626617, Maroto et al., 2018; 29632054), glioblastoma (Zureick et al., 2019; 31154346), and CNS embryonal tumor (Wu et al., 2020; 33344249), as well as a case of Hodgkin lymphoma (Perini et al., 2016; 27176796). In the prospective NCI_MATCH study, only 6.7% (1/15) of patients with TSC2_mutated solid tumors responded to everolimus, with the single response reported for 1 patient with uterine leiomyosarcoma (Adib et al., 2021; 33727259). Retrospective analyses of the RECORD_3, GRANITE_1, and EVOLVE_1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS (Voss et al., 2019; 30327302). Inactivating germline mutations in TSC2 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma (RCC) (Gomez, 1991; 2039135, Kandt et al., 1992; 1303246, European Chromosome 16 Tuberous Sclerosis Consortium, 1993; 8269512). TSC2 mutations account for approximately 75 to 80% of reported sporadic cases (Curatolo et al., 2008; 18722871). Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age (Curatolo et al., 2008; 18722871). In the appropriate clinical context, germline testing of TSC2 is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Nab_sirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nab_sirolimus is an intravenous nanoparticle albumin_bound mTOR inhibitor that is FDA approved to treat adult patients with advanced or metastatic perivascular epithelioid cell tumors (PEComas). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Based on a prospective study that showed a higher ORR for patients with TSC2_altered PEComas treated with nab_sirolimus than for those with neither TSC1_ nor TSC2_altered disease (Wagner et al., 2021; 34637337) and additional responses reported for individual patients with TSC2_altered endometrial stromal sarcoma, leiomyosarcoma, high grade sarcoma (NOS), or lymphangioleiomyomatosis (LAM) (Dickson et al., 2021; ASCO Abstract 3111), TSC2 mutation or loss may predict sensitivity to nab_sirolimus. </p> <p><b>Supporting Data:</b> Nab_sirolimus has been primarily investigated for the treatment of malignant PEComa but is also being explored to treat TSC2_ or TSC1_altered solid tumors. The Phase 2 AMPECT trial of nab_sirolimus for patients with malignant PEComa prospectively showed a significantly higher ORR for patients with TSC2_altered PEComa relative to those lacking TSC2 alterations (89%; 8/9 vs. 13%; 2/16, p<0.001)(Wagner et al., 2021; 34637337). In an expanded access program, 50% (3/6) of patients with TSC2_mutated malignant PEComa that had previously progressed on rapalogs, including everolimus, temsirolimus, and sirolimus, exhibited a PR when treated with nab_sirolimus (Dickson et al., 2021; CTOS Abstract 1818755). Outside of malignant PEComa, PRs were reported for individual patients with TSC2_altered endometrial stromal sarcoma, leiomyosarcoma, high_grade sarcoma, or lymphangioleiomyomatosis treated with nab_sirolimus (Dickson et al., 2021; ASCO Abstract 3111). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT03660930", "Include": "true"}, {"nctId": "NCT02693535", "Include": "true"}, {"nctId": "NCT04185831", "Include": "true"}, {"nctId": "NCT03778996", "Include": "true"}, {"nctId": "NCT02584647", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CHD2", "Include": "true", "Alterations": {"Alteration": {"Name": "rearrangement intron 38", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "rearrangement intron 38"}}, "Interpretation": "CHD2 encodes chromodomain helicase DNA binding protein 2, an ATPase/helicase that alters gene expression by modifying chromatin structure. Germline deletions and mutations in CHD2 are associated with several epilepsy syndromes, including Dravet syndrome and Lennox_Gastaut syndrome (Capelli et al., 2012; 22178256, Suls et al., 2013; 24207121, Lund et al., 2014; 24614520). Somatic mutations in CHD2 have been reported in 3% of all cancers in COSMIC, most frequently in skin (10.1%), esophagus (9.9%), pancreas (9.9%), liver (9.0%), gastric (8.7%), and prostate (7.7%) cancers (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). Loss_of_function mutations in CHD2 have been observed in nearly 50% of MSI_high colorectal and gastric cancers (Kim et al., 2011; 21447119), and differential expression of CHD2 was reported to be associated with colon cancer progression (Bandr\u00e9s et al., 2007; 17390049). Deletion of this gene has also been observed in a Hodgkin lymphoma cell line (Feys et al., 2007; 17606441). In agreement with these findings, preclinical research has suggested that CHD2 is a tumor suppressor that plays roles in the DNA damage response (Nagarajan et al., 2009; 19137022). There are no therapies available to directly address genomic alterations in CHD2.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GTSE1", "Include": "true", "Alterations": {"Alteration": {"Name": "R569C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R569C"}}, "Interpretation": "GTSE1 encodes a microtubule_interacting protein that interacts with p53 in response to DNA damage. Studies investigating the role of GTSE1 in cell invasiveness have generated mixed results. Mutations in this gene have been observed in 1_4% of various solid tumor types (COSMIC, Jun 2021)(Tate et al., 2019; 30371878). GTSE1 expression correlates with cell migration, invasive potential, and poor prognosis in breast cancer (Scolz et al., 2012; 23236459, Perez_Pena et al., 2017; 28423514), bladder cancer (Liu et al., 2019; 30414902), and hepatocellular carcinoma (Wu et al., 2017; 28698581, Guo et al., 2016; 27240802). However, no correlations were found between GTSE1 expression levels and clinical data in lung cancer (Tian et al., 2011; 22292647). There are no therapies available to target alterations in GTSE1.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, of which 40% were leiomyosarcomas and 25% were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). In smaller studies of soft tissue sarcoma, reports of MSI at any level have been rare, with the highest incidences between 11% (2/18) to 25% (10/40) of cases (Wooster al., 1994; 8162069, Kawaguchi et al., 2005; 15643505, Saito et al., 2003; 14562278, Suwa et al., 1999; 10370164, Garcia et al., 2006; 16619000, Aue et al., 1998; 9689926). In one study, MSI was reported to occur more frequently in high_grade soft tissue sarcomas compared with lower grade (Ruci\u0144ska et al., 2005; 15668629). However, published data investigating the prognostic implications of MSI in sarcoma are limited (PubMed, Jan 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RB1", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 18_27", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 18_27"}}, "Interpretation": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). RB1 mutations have been reported in 4.2% of soft tissue tumors analyzed in the COSMIC database (Jul 2021)(Tate et al., 2019; 30371878). Putative homozygous deletion of RB1 was reported in 7.7% of soft tissue sarcomas, most frequently in pleomorphic liposarcoma (25%, 6/24), myxofibrosarcoma (18%, 7/38), and leiomyosarcoma (11%, 3/27) (cBio_Barretina et al., 2010; 20601955). One study reported homozygous deletion of RB1 in 2/36 (5.5%) of undifferentiated pleomorphic sarcomas (previously called malignant fibrous histiocytoma), but loss of RB1 expression in 30/35 (86%), suggesting that loss of RB1 plays a pivotal role in the pathogenesis of this group of soft tissue sarcomas (Chibon et al., 2000; 11103795). In one study, decreased Rb protein expression was associated with improved overall survival in patients with soft tissue sarcoma (Shim et al, 2010; 20948919). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2018; 30373917, Oser et al., 2018; 30373918), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer. It should be noted that a trial of the Aurora kinase A inhibitor alisertib in advanced prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Rb inactivation may predict resistance to CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib, which act upstream of Rb (Condorelli et al., 2018; 29236940, Fry et al., 2004; 15542782, Dean et al., 2010; 20473330, Dean et al., 2012; 22767154, Garnett et al., 2012; 22460902, Roberts et al., 2012; 22302033, Patnaik et al., 2016; 27217383, O\u2019Leary et al., 2018; 30206110, Costa et al., 2020; 31594766, Chen et al., 2018; 29059158). Loss of Rb function has been associated with increased sensitivity to cytotoxic agents and chemotherapeutics in both preclinical studies and in patients with bladder or breast cancer (Derenzini et al., 2008; 18381962, Knudsen and Knudsen, 2008; 19143056). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "C176fs*71", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "C176fs*71"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations and homozygous deletion have been observed in 33% and 10% of sarcoma samples in the TCGA dataset, respectively (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). TP53 alterations appear to lead to chromosomal instability and drive oncogenesis in soft tissue sarcomas (P\u00e9rot et al., 2010; 20884963). One study of soft tissue sarcomas reported that TP53 non_frameshift mutations correlated with poor prognosis, including lymph node metastasis, increased rate of relapse, and decreased overall survival (Taubert et al., 1996; 8797580). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "03", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "03"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Soft tissue sarcomas harbor a median TMB of 2.5 Muts/Mb, with angiosarcoma (13.4%) and malignant peripheral nerve sheath tumor (MPNST) (8.2%) having the highest percentage of cases with high TMB (>20 Muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Increased mutation burden has been reported in undifferentiated pleomorphic sarcomas as compared to Ewing sarcomas or rhabdomyosarcomas (reviewed in Lim et al., 2015; 26330427, Brohl et al., 2014; 25010205, Chen et al., 2013; 24332040). Published data investigating the prognostic implications of TMB in sarcoma are limited (PubMed, Feb 2022). High TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380) and with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "Nanoparticle Albumin_Bound Rapamycin and Pazopanib Hydrochloride in Patients With Nonadipocytic Soft Tissue Sarcomas", "StudyPhase": "PHASE 1/2", "Target": "mTOR, FGFR3, KIT, FGFR1, VEGFRs, FGFR2", "Locations": "Washington", "NCTID": "NCT03660930", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, CDK4, CDK6, FLT3, CSF1R, KIT, RET, mTOR, EGFR, ERBB2, MEK, BRAF, SMO, DDR2, PARP, PD_1, CTLA_4, ERBB4", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "A MolEcularly Guided Anti_Cancer Drug Off_Label Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, MEK, mTOR", "Locations": "Uppsala (Sweden), Gothenburg (Sweden)", "NCTID": "NCT04185831", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "SM_88 as Maintenance Therapy for Advanced Ewing s Sarcoma Patients and as Salvage Therapy for Sarcoma Patients", "StudyPhase": "PHASE 2", "Target": "mTOR", "Locations": "California", "NCTID": "NCT03778996", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors", "StudyPhase": "PHASE 1/2", "Target": "mTOR, CSF1R, KIT, FLT3", "Locations": "Iowa, Michigan, Missouri, New York", "NCTID": "NCT02584647", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC2", "Alteration": "deletion exons 4_7", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "Inactivating TSC2 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "12869586", "FullCitation": "Inoki K, et al. Genes Dev. (2003) pmid: 12869586", "Include": "true"}, {"number": "1", "ReferenceId": "12906785", "FullCitation": "Tee AR, et al. Curr. Biol. (2003) pmid: 12906785", "Include": "true"}, {"number": "2", "ReferenceId": "11741833", "FullCitation": "Hodges AK, et al. Hum. Mol. Genet. (2001) pmid: 11741833", "Include": "true"}, {"number": "3", "ReferenceId": "16206276", "FullCitation": "Int. J. Cancer (2006) pmid: 16206276", "Include": "true"}, {"number": "4", "ReferenceId": "15340059", "FullCitation": "Li Y, et al. Mol. Cell. Biol. (2004) pmid: 15340059", "Include": "true"}, {"number": "5", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "6", "ReferenceId": "15236319", "FullCitation": "Lee_Jones L, et al. Genes Chromosomes Cancer (2004) pmid: 15236319", "Include": "true"}, {"number": "7", "ReferenceId": "22927055", "FullCitation": "Dickson MA, et al. Int. J. Cancer (2013) pmid: 22927055", "Include": "true"}, {"number": "8", "ReferenceId": "22748302", "FullCitation": "Hayashi T, et al. Hum. Pathol. (2012) pmid: 22748302", "Include": "true"}, {"number": "9", "ReferenceId": "22797305", "FullCitation": "Lee RS, et al. J. Clin. Invest. (2012) pmid: 22797305", "Include": "true"}, {"number": "10", "ReferenceId": "24216993", "FullCitation": "Ando K, et al. Cancers (Basel) (2013) pmid: 24216993", "Include": "true"}, {"number": "11", "ReferenceId": "19429803", "FullCitation": "Zenali MJ, et al. Ann. Clin. Lab. Sci. (2009) pmid: 19429803", "Include": "true"}, {"number": "12", "ReferenceId": "23714727", "FullCitation": "Zhang YX, et al. Clin. Cancer Res. (2013) pmid: 23714727", "Include": "true"}, {"number": "13", "ReferenceId": "22821997", "FullCitation": "Brewer Savannah KJ, et al. Clin. Cancer Res. (2012) pmid: 22821997", "Include": "true"}, {"number": "14", "ReferenceId": "23605780", "FullCitation": "Curr Oncol Rep (2013) pmid: 23605780", "Include": "true"}, {"number": "15", "ReferenceId": "25782670", "FullCitation": "Kwiatkowski DJ, et al. Eur J Hum Genet (2015) pmid: 25782670", "Include": "true"}, {"number": "16", "ReferenceId": "34217357", "FullCitation": "Luo C, et al. Orphanet J Rare Dis (2021) pmid: 34217357", "Include": "true"}, {"number": "17", "ReferenceId": "31597506", "FullCitation": "Wang T, et al. Cancer Biol Ther (2020) pmid: 31597506", "Include": "true"}, {"number": "18", "ReferenceId": "33575217", "FullCitation": "Guo G, et al. Front Oncol (2020) pmid: 33575217", "Include": "true"}, {"number": "19", "ReferenceId": "29764404", "FullCitation": "Espinosa M, et al. BMC Cancer (2018) pmid: 29764404", "Include": "true"}, {"number": "20", "ReferenceId": "28547571", "FullCitation": "Chuang CK, et al. Int Urol Nephrol (2017) pmid: 28547571", "Include": "true"}, {"number": "21", "ReferenceId": "20048174", "FullCitation": "Wagner AJ, et al. J. Clin. Oncol. (2010) pmid: 20048174", "Include": "true"}, {"number": "22", "ReferenceId": "34637337", "FullCitation": "Wagner AJ, et al. J Clin Oncol (2021) pmid: 34637337", "Include": "true"}, {"number": "23", "ReferenceId": "33727259", "FullCitation": "Adib E, et al. Clin Cancer Res (2021) pmid: 33727259", "Include": "true"}, {"number": "24", "ReferenceId": "31653662", "FullCitation": "Nassar AH, et al. Mol Cancer Ther (2020) pmid: 31653662", "Include": "true"}, {"number": "25", "ReferenceId": "3032730", "FullCitation": "De S, et al. Gegenbaurs Morphol Jahrb (1986) pmid: 3032730", "Include": "true"}, {"number": "26", "ReferenceId": "25295501", "FullCitation": "Wagle N, et al. N. Engl. J. Med. (2014) pmid: 25295501", "Include": "true"}, {"number": "27", "ReferenceId": "26626617", "FullCitation": "Tannir NM, et al. Eur. Urol. (2016) pmid: 26626617", "Include": "true"}, {"number": "28", "ReferenceId": "29632054", "FullCitation": "Maroto P, et al. J Natl Compr Canc Netw (2018) pmid: 29632054", "Include": "true"}, {"number": "29", "ReferenceId": "31154346", "FullCitation": "Zureick AH, et al. BMJ Case Rep (2019) pmid: 31154346", "Include": "true"}, {"number": "30", "ReferenceId": "33344249", "FullCitation": "Hu W, et al. Front Oncol (2020) pmid: 33344249", "Include": "true"}, {"number": "31", "ReferenceId": "27176796", "FullCitation": "Perini GF, et al. Blood Cancer J (2016) pmid: 27176796", "Include": "true"}, {"number": "32", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "33", "ReferenceId": "2039135", "FullCitation": "Ann. N. Y. Acad. Sci. (1991) pmid: 2039135", "Include": "true"}, {"number": "34", "ReferenceId": "1303246", "FullCitation": "Kandt RS, et al. Nat. Genet. (1992) pmid: 1303246", "Include": "true"}, {"number": "35", "ReferenceId": "8269512", "FullCitation": "Cell (1993) pmid: 8269512", "Include": "true"}, {"number": "36", "ReferenceId": "18722871", "FullCitation": "Curatolo P, et al. Lancet (2008) pmid: 18722871", "Include": "true"}, {"number": "37", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "38", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "39", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "40", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "41", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "42", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "43", "ReferenceId": "23401795", "FullCitation": "Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795", "Include": "true"}, {"number": "44", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "45", "ReferenceId": "8162069", "FullCitation": "Wooster R, et al. Nat. Genet. (1994) pmid: 8162069", "Include": "true"}, {"number": "46", "ReferenceId": "15643505", "FullCitation": "Kawaguchi K, et al. Oncol. Rep. (2005) pmid: 15643505", "Include": "true"}, {"number": "47", "ReferenceId": "14562278", "FullCitation": "Saito T, et al. Hum. Pathol. (2003) pmid: 14562278", "Include": "true"}, {"number": "48", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "49", "ReferenceId": "16619000", "FullCitation": "Garcia JJ, et al. Mod. Pathol. (2006) pmid: 16619000", "Include": "true"}, {"number": "50", "ReferenceId": "9689926", "FullCitation": "Aue G, et al. Cancer Genet. Cytogenet. (1998) pmid: 9689926", "Include": "true"}, {"number": "51", "ReferenceId": "15668629", "FullCitation": "Ruci\u0144ska M, et al. Med. Sci. Monit. (2005) pmid: 15668629", "Include": "true"}, {"number": "52", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "53", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "54", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "55", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "56", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "57", "ReferenceId": "23236459", "FullCitation": "Scolz M, et al. PLoS ONE (2012) pmid: 23236459", "Include": "true"}, {"number": "58", "ReferenceId": "28423514", "FullCitation": "P\u00e9rez_Pe\u00f1a J, et al. Oncotarget (2017) pmid: 28423514", "Include": "true"}, {"number": "59", "ReferenceId": "30414902", "FullCitation": "Liu A, et al. Int. J. Biol. Macromol. (2019) pmid: 30414902", "Include": "true"}, {"number": "60", "ReferenceId": "28698581", "FullCitation": "Wu X, et al. Sci Rep (2017) pmid: 28698581", "Include": "true"}, {"number": "61", "ReferenceId": "27240802", "FullCitation": "Guo L, et al. Cell Biol. Toxicol. (2016) pmid: 27240802", "Include": "true"}, {"number": "62", "ReferenceId": "22292647", "FullCitation": "Tian T, et al. Asian Pac. J. Cancer Prev. (2011) pmid: 22292647", "Include": "true"}, {"number": "63", "ReferenceId": "22178256", "FullCitation": "Capelli LP, et al. Eur J Med Genet (2012) pmid: 22178256", "Include": "true"}, {"number": "64", "ReferenceId": "24207121", "FullCitation": "Suls A, et al. Am. J. Hum. Genet. (2013) pmid: 24207121", "Include": "true"}, {"number": "65", "ReferenceId": "24614520", "FullCitation": "Lund C, et al. Epilepsy Behav (2014) pmid: 24614520", "Include": "true"}, {"number": "66", "ReferenceId": "21447119", "FullCitation": "Kim MS, et al. Histopathology (2011) pmid: 21447119", "Include": "true"}, {"number": "67", "ReferenceId": "17390049", "FullCitation": "Bandr\u00e9s E, et al. Oncol. Rep. (2007) pmid: 17390049", "Include": "true"}, {"number": "68", "ReferenceId": "17606441", "FullCitation": "Feys T, et al. Haematologica (2007) pmid: 17606441", "Include": "true"}, {"number": "69", "ReferenceId": "19137022", "FullCitation": "Nagarajan P, et al. Oncogene (2009) pmid: 19137022", "Include": "true"}, {"number": "70", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "71", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "72", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "73", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "74", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "75", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "76", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "77", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "78", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "79", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "80", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "81", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "82", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "83", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "84", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "85", "ReferenceId": "26330427", "FullCitation": "Lim J, et al. Clin. Cancer Res. (2015) pmid: 26330427", "Include": "true"}, {"number": "86", "ReferenceId": "25010205", "FullCitation": "Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205", "Include": "true"}, {"number": "87", "ReferenceId": "24332040", "FullCitation": "Chen X, et al. Cancer Cell (2013) pmid: 24332040", "Include": "true"}, {"number": "88", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "89", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "90", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "91", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "92", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "93", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "94", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "95", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "96", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "97", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "98", "ReferenceId": "18650841", "FullCitation": "Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841", "Include": "true"}, {"number": "99", "ReferenceId": "19143056", "FullCitation": "Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056", "Include": "true"}, {"number": "100", "ReferenceId": "20594292", "FullCitation": "Berge EO, et al. Mol. Cancer (2010) pmid: 20594292", "Include": "true"}, {"number": "101", "ReferenceId": "16936740", "FullCitation": "Giacinti C, et al. Oncogene (2006) pmid: 16936740", "Include": "true"}, {"number": "102", "ReferenceId": "9342358", "FullCitation": "Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358", "Include": "true"}, {"number": "103", "ReferenceId": "10486322", "FullCitation": "Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322", "Include": "true"}, {"number": "104", "ReferenceId": "1534305", "FullCitation": "Qin XQ, et al. Genes Dev. (1992) pmid: 1534305", "Include": "true"}, {"number": "105", "ReferenceId": "16360038", "FullCitation": "Rubin SM, et al. Cell (2005) pmid: 16360038", "Include": "true"}, {"number": "106", "ReferenceId": "16449662", "FullCitation": "Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662", "Include": "true"}, {"number": "107", "ReferenceId": "11103795", "FullCitation": "Chibon F, et al. Cancer Res. (2000) pmid: 11103795", "Include": "true"}, {"number": "108", "ReferenceId": "20948919", "FullCitation": "Shim BY, et al. Cancer Res Treat (2010) pmid: 20948919", "Include": "true"}, {"number": "109", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "110", "ReferenceId": "30373917", "FullCitation": "Gong X, et al. Cancer Discov (2019) pmid: 30373917", "Include": "true"}, {"number": "111", "ReferenceId": "30373918", "FullCitation": "Oser MG, et al. Cancer Discov (2019) pmid: 30373918", "Include": "true"}, {"number": "112", "ReferenceId": "30232224", "FullCitation": "Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224", "Include": "true"}, {"number": "113", "ReferenceId": "21955141", "FullCitation": "Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141", "Include": "true"}, {"number": "114", "ReferenceId": "21875955", "FullCitation": "Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955", "Include": "true"}, {"number": "115", "ReferenceId": "29236940", "FullCitation": "Condorelli R, et al. Ann. Oncol. (2018) pmid: 29236940", "Include": "true"}, {"number": "116", "ReferenceId": "15542782", "FullCitation": "Fry DW, et al. Mol. Cancer Ther. (2004) pmid: 15542782", "Include": "true"}, {"number": "117", "ReferenceId": "20473330", "FullCitation": "Dean JL, et al. Oncogene (2010) pmid: 20473330", "Include": "true"}, {"number": "118", "ReferenceId": "22767154", "FullCitation": "Dean JL, et al. Cell Cycle (2012) pmid: 22767154", "Include": "true"}, {"number": "119", "ReferenceId": "22460902", "FullCitation": "Garnett MJ, et al. Nature (2012) pmid: 22460902", "Include": "true"}, {"number": "120", "ReferenceId": "22302033", "FullCitation": "Roberts PJ, et al. J. Natl. Cancer Inst. (2012) pmid: 22302033", "Include": "true"}, {"number": "121", "ReferenceId": "27217383", "FullCitation": "Patnaik A, et al. Cancer Discov (2016) pmid: 27217383", "Include": "true"}, {"number": "122", "ReferenceId": "30206110", "FullCitation": "O Leary B, et al. Cancer Discov (2018) pmid: 30206110", "Include": "true"}, {"number": "123", "ReferenceId": "31594766", "FullCitation": "Costa C, et al. Cancer Discov (2019) pmid: 31594766", "Include": "true"}, {"number": "124", "ReferenceId": "29059158", "FullCitation": "Chen SH, et al. Oncogene (2018) pmid: 29059158", "Include": "true"}, {"number": "125", "ReferenceId": "18381962", "FullCitation": "Derenzini M, et al. Clin. Cancer Res. (2008) pmid: 18381962", "Include": "true"}, {"number": "126", "ReferenceId": "24282159", "FullCitation": "Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159", "Include": "true"}, {"number": "127", "ReferenceId": "22553621", "FullCitation": "Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621", "Include": "true"}, {"number": "128", "ReferenceId": "21139478", "FullCitation": "Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478", "Include": "true"}, {"number": "129", "ReferenceId": "19959033", "FullCitation": "Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033", "Include": "true"}, {"number": "130", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "131", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "132", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "133", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "134", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "135", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "136", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "137", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "138", "ReferenceId": "20884963", "FullCitation": "P\u00e9rot G, et al. Am. J. Pathol. (2010) pmid: 20884963", "Include": "true"}, {"number": "139", "ReferenceId": "8797580", "FullCitation": "Taubert H, et al. Cancer Res. (1996) pmid: 8797580", "Include": "true"}, {"number": "140", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "141", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "142", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "143", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "144", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "145", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "146", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "147", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "148", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "149", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "150", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "151", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "152", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "153", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "154", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "155", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "156", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "157", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "158", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "159", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "160", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "161", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "162", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "163", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "164", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "165", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "166", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "167", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "168", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "169", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "170", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "171", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "172", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "173", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_03_09 21:52:02", "OpName": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "801x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "3 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SOFT TISSUE", "disease_ontology": "Soft tissue sarcoma (NOS)", "flowcell_analysis": "2000020638", "gender": "female", "pathology_diagnosis": "Ewing_like sarcoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.10.1", "purity_assessment": "30.0", "specimen": "ORD_1308441_01*US1257626.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1308441_01", "test_type": "HemeComplete", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "D2", "mean_exon_depth": "820.78", "name": "SQ_US1257626.01_1", "nucleic_acid_type": "DNA"}, {"bait_set": "R2", "mean_exon_depth": "445.78", "name": "SQ_US1257626.01_2", "nucleic_acid_type": "RNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4566", "cds_effect": "1705C>T", "depth": "565", "equivocal": "false", "functional_effect": "missense", "gene": "GTSE1", "percent_reads": "45.66", "position": "chr22:46722532", "protein_effect": "R569C", "status": "known", "strand": "+", "transcript": "NM_016426", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.3906", "cds_effect": "526delT", "depth": "768", "equivocal": "false", "functional_effect": "frameshift", "gene": "TP53", "percent_reads": "39.06", "position": "chr17:7578403", "protein_effect": "C176fs*71", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.6616", "cds_effect": "879T>G", "depth": "591", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "66.16", "position": "chr13:32906494", "protein_effect": "D293E", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.5385", "cds_effect": "81_92delCCCGCAGCAGCC", "depth": "195", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "FBXO11", "percent_reads": "53.85", "position": "chr2:48132767", "protein_effect": "Q29_P32del", "status": "unknown", "strand": "_", "transcript": "NM_001190274", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.5157", "cds_effect": "1370_1372delAGG", "depth": "669", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "DAXX", "percent_reads": "51.57", "position": "chr6:33287880", "protein_effect": "E457del", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.2117", "cds_effect": "2982C>A", "depth": "888", "equivocal": "false", "functional_effect": "nonsense", "gene": "SETBP1", "percent_reads": "21.17", "position": "chr18:42532287", "protein_effect": "Y994*", "status": "unknown", "strand": "+", "transcript": "NM_015559", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.4871", "cds_effect": "3862_3864delAAG", "depth": "349", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "GPR124", "percent_reads": "48.71", "position": "chr8:37699717", "protein_effect": "K1288del", "status": "unknown", "strand": "+", "transcript": "NM_032777", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.6723", "cds_effect": "3891G>C", "depth": "534", "equivocal": "false", "functional_effect": "missense", "gene": "FANCA", "percent_reads": "67.23", "position": "chr16:89806445", "protein_effect": "K1297N", "status": "unknown", "strand": "_", "transcript": "NM_000135", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.5043", "cds_effect": "212T>C", "depth": "587", "equivocal": "false", "functional_effect": "missense", "gene": "PCLO", "percent_reads": "50.43", "position": "chr7:82791697", "protein_effect": "V71A", "status": "unknown", "strand": "_", "transcript": "NM_014510", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.5", "cds_effect": "1595C>T", "depth": "762", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "50.0", "position": "chr7:2969684", "protein_effect": "T532M", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.0976", "cds_effect": "47T>A", "depth": "615", "equivocal": "false", "functional_effect": "missense", "gene": "P2RY8", "percent_reads": "9.76", "position": "chrX:1585405", "protein_effect": "M16K", "status": "unknown", "strand": "_", "transcript": "NM_178129", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"allele_fraction": "0.4335", "cds_effect": "665G>A", "depth": "496", "equivocal": "false", "functional_effect": "missense", "gene": "JAK3", "percent_reads": "43.35", "position": "chr19:17953321", "protein_effect": "R222H", "status": "unknown", "strand": "_", "transcript": "NM_000215", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": {"copy_number": "0", "equivocal": "false", "gene": "RB1", "number_of_exons": "10 of 27", "position": "chr13:48976846_49054234", "ratio": "0.67", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}}, "rearrangements": {"rearrangement": [{"description": "TSC2(NM_000548) deletion exon 4 _ intron 7", "equivocal": "false", "in_frame": "unknown", "other_gene": "TSC2", "pos1": "chr16:2103207_2103442", "pos2": "chr16:2106246_2106480", "status": "likely", "supporting_read_pairs": "65", "targeted_gene": "TSC2", "type": "deletion", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}, {"description": "CHD2(NM_001271) rearrangement intron 38", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr15:93567558_93567792", "pos2": "chr8:24071700_24071843", "status": "likely", "supporting_read_pairs": "13", "targeted_gene": "CHD2", "type": "truncation", "dna_evidence": {"sample": "SQ_US1257626.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}